Med. praxi. 2011;8(3):104-110

New treatment for postmenopausal osteoporosis

doc.MUDr.Pavel Horák, CSc., MUDr.Martina Skácelová, MUDr.Martin Žurek, MUDr.Andrea Smržová, MUDr.Hana Ciferská
III. interní klinika FN a LF UP Olomouc

The overview article brings information on the new antiporotic drugs for postmenopausal osteoporosis. It deals with intravenous bisphosphonates

– ibandronate and zoledronate, with new biological drug denosumab blocking RANKL and finally with osteoanabolic

derivates of parathormon 1–34 and 1–84 PTH.

Keywords: osteoporosis, treatment, undesirable side effects

Published: March 23, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Horák P, Skácelová M, Žurek M, Smržová A, Ciferská H. New treatment for postmenopausal osteoporosis. Med. praxi. 2011;8(3):104-110.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. www.shef.ac.uk/frax/.
    2. Broulík P. Osteoporóza. Praha: Maxdorf Jessenius, 1999.
    3. Epstein S, Zaidi M. Biological properties and mechanism of action of ibandronate: Aplication to the treatment of osteoporosis. Bone 2005; 37: 433-440. Go to original source... Go to PubMed...
    4. Delmas PD, Recker RR, Chesnut CH, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis Int 2004; 15: 792-8. Go to original source... Go to PubMed...
    5. Chesnut III CH, Skag A, Christiansen C, et al. Effect of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249. Go to original source... Go to PubMed...
    6. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum 2006; 54: 1838-1846. Go to original source... Go to PubMed...
    7. Stakkestad JA, Lakatos P, Lorenc R, et al. Monthly oral ibandronate is effective and well tolerated after 3 years: the MOBILE long term extension. Clin Rheumatol 2008; 27: 955-960. Go to original source... Go to PubMed...
    8. Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injection in postmenopausal osteoporosis: 2 years results from DIVA study. J Rheumatol 2008; 38: 488-497.
    9. Cranney A, Wells GA, Yetisir E, et al. Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporosis Int 2009; 20: 291-297. Go to original source... Go to PubMed...
    10. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007; 356: 1809-1822. Go to original source... Go to PubMed...
    11. Lyles KW, Colón-Emeric CS, Magazine JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture N Engl J Med 2007; 357: 1799-1809. Go to original source... Go to PubMed...
    12. Cummings SR, Martin JS, McClung MR. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-765. Go to original source... Go to PubMed...
    13. Brown JP, Prince RL, Deal C, et al. Comparison of the Effect of Denosumab and Alendronate on Bone Mineral Density and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial. J Bone Miner Res 2009; 24: 153-161. Go to original source... Go to PubMed...
    14. Kendler DL, Roux C, Benhamou CL, et al. Effects of Denosumab on Bone Mineral Density and Bone Turnover in Postmenopausal Women Transitioning from Alendronate Therapy [Published online ahead of print July 13, 2009]. J Bone Miner Res. doi: 10.1359/JBMR.090716. Go to original source... Go to PubMed...
    15. Neer RM, Arnaud CD, Zancheta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001; 344: 1434-1441. Go to original source... Go to PubMed...
    16. Saag, KG, Shane, E, Boonen, S, et al. Teriparatide or Alendronate in Glucocorticoid-Induced Osteoporosis. N Engl J Med 2007; 357: 2028-2039. Go to original source... Go to PubMed...
    17. Greenspan SL, Bone HG, Ettinger MP, et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 2007; 146: 326-331. Go to original source... Go to PubMed...
    18. Bogado CE, Zanchetta JR, Mango A, et al. Effects of Parathyroid Hormone 1-84 on Cortical and Trabecular Bone at the Hip as Assessed by QCT: Results at 18 months from the TOP Study. J Bone Miner Res 2005; 20: S22.
    19. Hodsman AB, Hanley DA, Ettinger MP, et al. Efficacy and safety of human parathyroid hormone - (1-84) in increasing bone mineral density in postmenopausal osteoporosis. J Clin Endocrinol Metab 2003; 88: 5212-5218. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.